Citadel Advisors
FLGT icon

Citadel Advisors’s Fulgent Genetics FLGT Stock Holding History

Citadel Advisors’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.57M Buy
174,180
+121,232
+229% +$2.06M ﹤0.01% 5340
2026
Q1 		$842K Sell
52,948
-190,176
-78% -$4.13M ﹤0.01% 8055
2025
Q4 		$6.39M Sell
243,124
-128,352
-35% -$3.33M ﹤0.01% 3904
2025
Q3 		$8.4M Sell
371,476
-232,177
-38% -$4.78M ﹤0.01% 3522
2025
Q2 		$12M Buy
603,653
+167,911
+39% +$3.27M ﹤0.01% 2776
2025
Q1 		$7.36M Buy
435,742
+209,123
+92% +$3.56M ﹤0.01% 3298
2024
Q4 		$4.19M Sell
226,619
-76,299
-25% -$1.49M ﹤0.01% 4257
2024
Q3 		$6.58M Buy
302,918
+116,683
+63% +$2.61M ﹤0.01% 3511
2024
Q2 		$3.65M Buy
186,235
+73,796
+66% +$1.54M ﹤0.01% 4258
2024
Q1 		$2.44M Sell
112,439
-10,441
-8% -$259K ﹤0.01% 5141
2023
Q4 		$3.55M Sell
122,880
-70,136
-36% -$1.88M ﹤0.01% 4348
2023
Q3 		$5.16M Sell
193,016
-271,406
-58% -$9.27M ﹤0.01% 3598
2023
Q2 		$17.2M Buy
464,422
+166,247
+56% +$5.79M ﹤0.01% 2040
2023
Q1 		$9.31M Buy
298,175
+240,849
+420% +$7.75M ﹤0.01% 2904
2022
Q4 		$1.71M Sell
57,326
-107,467
-65% -$3.85M ﹤0.01% 5769
2022
Q3 		$6.28M Buy
164,793
+42,057
+34% +$2.11M ﹤0.01% 3509
2022
Q2 		$6.69M Buy
122,736
+61,468
+100% +$3.38M ﹤0.01% 3280
2022
Q1 		$3.82M Sell
61,268
-167,624
-73% -$11M ﹤0.01% 4696
2021
Q4 		$23M Sell
228,892
-28,528
-11% -$2.51M ﹤0.01% 1866
2021
Q3 		$23.2M Buy
257,420
+243,672
+1,772% +$22.1M ﹤0.01% 1835
2021
Q2 		$1.27M Sell
13,748
-144,784
-91% -$11.6M ﹤0.01% 7729
2021
Q1 		$15.3M Buy
158,532
+146,623
+1,231% +$15.1M ﹤0.01% 2339
2020
Q4 		$620K Buy
11,909
+1,723
+17% +$72K ﹤0.01% 7745
2020
Q3 		$408K Buy
+10,186
New +$319K ﹤0.01% 7626

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors's FLGT Position: Q2 2026 in Review

Citadel Advisors increased its Fulgent Genetics (FLGT) stake by 229% in Q2 2026, buying an estimated $2.06M and bringing the position to 174,180 shares worth $3.57M. The position accounts for ﹤0.01% of the portfolio, ranked #5340.

Citadel Advisors first reported a position in FLGT in Q3 2020 and has held it in 24 quarters since. The position peaked at $23.2M in Q3 2021. 141 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

  • Citadel Advisors held 174,180 shares of Fulgent Genetics worth $3.57M as of Q2 2026.
  • Citadel Advisors bought 121,232 Fulgent Genetics shares in Q2 2026, an estimated $2.06M.
  • Fulgent Genetics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5340 holding.
  • Citadel Advisors first reported a position in Fulgent Genetics in Q3 2020 and has held it in 24 quarters since.
  • Citadel Advisors's Fulgent Genetics position peaked at $23.2M in Q3 2021.
  • 141 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.